Comparative Pharmacology
Head-to-head clinical analysis: DARUNAVIR versus LEXIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARUNAVIR versus LEXIVA.
DARUNAVIR vs LEXIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Darunavir is an HIV-1 protease inhibitor that selectively inhibits the cleavage of HIV-1 encoded Gag-Pol polyproteins in virus-infected cells, thereby preventing formation of mature infectious virions.
Fosamprenavir is a prodrug of amprenavir, a protease inhibitor (PI) that competitively inhibits HIV-1 protease, preventing cleavage of viral Gag-Pol polyprotein, resulting in immature, non-infectious viral particles.
600 mg orally twice daily with ritonavir 100 mg twice daily or 800 mg orally once daily with cobicistat 150 mg once daily, taken with food.
1400 mg orally twice daily (with ritonavir 100 mg) or 1400 mg orally once daily (with ritonavir 100 mg and cobicistat 150 mg). For treatment-naïve patients, 1400 mg orally once daily with ritonavir 100 mg or cobicistat 150 mg.
None Documented
None Documented
Clinical Note
moderateDarunavir + Tenofovir disoproxil
"The serum concentration of Tenofovir disoproxil can be increased when it is combined with Darunavir."
Clinical Note
moderateDarunavir + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Darunavir."
Clinical Note
moderateDarunavir + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Darunavir."
Clinical Note
moderateDarunavir + Clotrimazole
Terminal elimination half-life is approximately 15 hours when co-administered with low-dose ritonavir, supporting once-daily dosing.
Terminal elimination half-life is 2.8 to 5.7 hours; with ritonavir boosting, half-life increases to 7-10 hours, allowing once-daily dosing.
Primarily fecal (79.5% as unchanged drug or metabolites), with renal excretion accounting for approximately 13.9% (8.9% unchanged).
Renal (approximately 82% in urine, with 14% as parent drug and 68% as metabolites); fecal (approximately 16%, with 7% as parent drug).
Category A/B
Category C
Protease Inhibitor
Protease Inhibitor
"The metabolism of Clotrimazole can be decreased when combined with Darunavir."